Compare Firy Inc. (FIRY) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Firy Inc. vs Sana Biotechnology Inc — how do they compare? Firy Inc. trades at $9.98 (market cap $159.51M), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Sana Biotechnology Inc is far larger — about 7.1× Firy Inc.'s market cap, and Firy Inc. is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| FIRY | SANA | |
|---|---|---|
Market Cap | $159.51M | $1.13B |
Sector | Consumer Cyclical | Health |
52-Week High | $12.45 | $5.92 |
52-Week Low | $2.28 | $2.68 |
Enterprise Value | $103.18M | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIRY trades at $9.98, down 4.77% in the last 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 revenue growth and a slight earnings beat, yet maintains negative net income margins and cash flow challenges. Recent news includes a legal victory awarding $719 million and a rebrand from Skillz Inc.
Outlook remains cautious due to persistent losses and cash burn, though the legal win provides a liquidity boost. Risks include high SG&A costs and competitive pressures, while analyst sentiment is mixed with a majority hold rating. Investors should weigh the potential from strategic shifts against fundamental weaknesses.
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
